[HTML][HTML] Right-vs. left-sided metastatic colorectal cancer: differences in tumor biology and bevacizumab efficacy

P Ulivi, E Scarpi, E Chiadini, G Marisi… - International journal of …, 2017 - mdpi.com
There is evidence of a different response to treatment with regard to the primary tumor
localization (right-sided or left-sided) in patients with metastatic colorectal cancer (mCRC) …

[HTML][HTML] Epigenome-wide methylation analysis of colorectal carcinoma, adenoma and normal tissue reveals novel biomarkers addressing unmet clinical needs

K Janssens, I Neefs, J Ibrahim, A Schepers… - Clinical …, 2023 - Springer
Background Biomarker discovery in colorectal cancer has mostly focused on methylation
patterns in normal and colorectal tumor tissue, but adenomas remain understudied …

KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics

IA Voutsadakis - Critical Reviews in Oncology/Hematology, 2023 - Elsevier
Background Colorectal cancer is one of the most prevalent malignancies and its molecular
pathogenesis has been intensely investigated for several decades. As a result, great …

[PDF][PDF] Differences in clinical features and oncologic outcomes between metastatic right and left colon cancer

K Kim, YW Kim, H Shim, BR Kim, HY Kwon - J buon, 2018 - researchgate.net
Summary Approximately 20% to 25% of patients with colorectal cancer (CRC) have distant
organ metastasis at the time of initial diagnosis. The primary tumor location has been …

[HTML][HTML] Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer

Y Shimada, H Kameyama, M Nagahashi, H Ichikawa… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Objectives Anti-epidermal growth factor receptor (EGFR) therapy has been found to be more
effective against left-sided colorectal cancer (LCRC) than right-sided colorectal cancer …

Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy

C Gallois, J Taieb, D Le Corre, K Le Malicot… - Clinical Cancer …, 2018 - AACR
Purpose: There are conflicting results concerning the prognostic value of the CpG island
methylator phenotype (CIMP) in patients with nonmetastatic colon cancer. We studied this …

[HTML][HTML] Wingless/It/β-catenin signaling in liver metastasis from colorectal cancer: A focus on biological mechanisms and therapeutic opportunities

F Selvaggi, T Catalano, R Lattanzio… - World Journal of …, 2023 - ncbi.nlm.nih.gov
The liver is the most common site of metastases in patients with colorectal cancer. Colorectal
liver metastases (CRLMs) are the result of molecular mechanisms that involve different cells …

[HTML][HTML] Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and …

S Hegewisch-Becker, S Nöpel-Dünnebacke… - European Journal of …, 2018 - Elsevier
Background The major prognostic relevance of primary tumour location (LPT) in advanced
colorectal cancer was shown in large retrospective studies, but quantitative estimates are …

Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer

F Bormann, S Stinzing, S Tierling… - … Journal of Cancer, 2019 - Wiley Online Library
Expression of the epidermal growth factor ligands amphiregulin (AREG) and epiregulin
(EREG) is positively correlated with a response to EGFR‐targeted therapies in colorectal …

[HTML][HTML] Significance of amphiregulin (AREG) for the outcome of low and high grade astrocytoma patients

G Steponaitis, A Kazlauskas, D Skiriute… - Journal of …, 2019 - ncbi.nlm.nih.gov
Background: Amphiregulin (AREG) is one of the ligands of the epidermal growth factor
receptor which levels was shown to have a tight coherence with various types of cancer …